Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
3.820
-0.070 (-1.80%)
At close: Sep 17, 2025, 4:00 PM EDT
3.840
+0.020 (0.52%)
After-hours: Sep 17, 2025, 5:01 PM EDT
Precigen Revenue
Precigen had revenue of $856.00K in the quarter ending June 30, 2025, with 19.39% growth. This brings the company's revenue in the last twelve months to $4.34M, down -1.12% year-over-year. In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%.
Revenue (ttm)
$4.34M
Revenue Growth
-1.12%
P/S Ratio
259.85
Revenue / Employee
$30,350
Employees
143
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
| Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PGEN News
- 14 days ago - Precigen Announces Up to $125 Million Non-Dilutive Financing - PRNewsWire
- 15 days ago - Precigen, Inc. - Special Call - Seeking Alpha
- 23 days ago - Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright - PRNewsWire
- 26 days ago - Undercovered Dozen: Precigen, ONEOK, Bitmine And More - Seeking Alpha
- 4 weeks ago - Precigen: This Billion-Dollar Approval Is Still Undervalued - Seeking Alpha
- 4 weeks ago - Why Is Precigen Stock Surging On Friday? - Benzinga
- 4 weeks ago - US FDA approves Precigen's immunotherapy for rare respiratory disease - Reuters
- 4 weeks ago - Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PRNewsWire